Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 108

Sort by

Sort Order Select

Journal Articles

Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of Tyrosine Kinase Inhibitor Treatment Failure: A Report from the Residiag Study

Hippolyte Guerineau, Jean-Michel Cayuela, Stéphanie Dulucq, Violaine Tran Quang, Sihem Tarfi, Quentin Barathon, Corine Joy, Orianne Wagner-Ballon, Stéphane Morisset, Franck E. Nicolini, Lydia Roy, Sébastien Maury, Gabriel Etienne, Delphine Rea, Ivan Sloma

Blood (2023) 142 (Supplement 1): 4540.

https://doi.org/10.1182/blood-2023-186271

Published: 2023

Journal Articles

Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study

Blood (2023) 142 (Supplement 1): 1800.

https://doi.org/10.1182/blood-2023-173132

Published: 2023

Journal Articles

T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Blood (2023) 142 (Supplement 1): 445.

https://doi.org/10.1182/blood-2023-181571

Published: 2023

Journal Articles

Last Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase” in Patients with TKI-Resistant or Intolerant CML

Emilie Cayssials, Gabriel Etienne, Ali G Turhan, Philippe Rousselot, Valerie Coiteux, Marc G. Berger, Francoise Huguet, Agnes Guerci-Bresler

Blood (2022) 140 (Supplement 1): 6776–6777.

https://doi.org/10.1182/blood-2022-166111

Published: 2022

Journal Articles

Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group

Blood (2022) 140 (Supplement 1): 1501–1503.

https://doi.org/10.1182/blood-2022-169324

Published: 2022

Journal Articles

Treatment Patterns, Tolerance, and Clinical Response of Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients (Including Those Harboring the T315I Mutation) Experiencing Multiple Tyrosine Kinase Inhibitor Failure: A Multi-Center Retrospective Chart Review Analysis

Franck E. Nicolini, Francoise Huguet, Lynn Huynh, Churong Xu, Christophe Bouvier, Aurore Yocolly, Gabriel Etienne

Blood (2022) 140 (Supplement 1): 9656–9658.

https://doi.org/10.1182/blood-2022-160268

Published: 2022

Journal Articles

Therapy Related Myeloid Neoplasms Following PARP Inhibitors : Real-Life Experience

Blood (2022) 140 (Supplement 1): 12335–12338.

https://doi.org/10.1182/blood-2022-163478

Published: 2022

Journal Articles

Prospective Follow-up of Patients with Myelofibrosis (MF) and Treated with Ruxolitinib in France: The Rumycup Study

Jean-Jacques Kiladjian, Françoise Boyer perrard, Kamel Laribi, Jean-Christophe Ianotto, Dana Ranta, Omar Benbrahim, Serge Bologna, Pascale Cony-Makhoul, Alberto Santagostino, Hacene Zerazhi, Abla Slimani, Olivier Fitoussi, Gabriel Etienne

Blood (2022) 140 (Supplement 1): 3968–3969.

https://doi.org/10.1182/blood-2022-156628

Published: 2022

Journal Articles

Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line, in Real-Life Conditions: Influence of Switching to Another TKI Prior to Cessation.

Franck E. Nicolini, Vincent Alcazer, Pascale Cony-Makhoul, Stéphanie Dulucq, Sandrine Hayette, Stéphane Morisset, Rachel Parat, Christophe Bouvier, Gabriel Etienne

Blood (2022) 140 (Supplement 1): 3918–3919.

https://doi.org/10.1182/blood-2022-163376

Published: 2022

Journal Articles

The Outcome of Treatment-Free Remission after First-Line Nilotinib or Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients Is Different

Franck E. Nicolini, Vincent Alcazer, Stephanie Dulucq, Sandrine Hayette, Jean-Michel Cayuela, Stephane Morisset, Christophe Bouvier, Francois-Xavier Mahon, Gabriel Etienne, Delphine Rea

Blood (2021) 138 (Supplement 1): 2552.

https://doi.org/10.1182/blood-2021-146722

Published: 2021

Journal Articles

Treatment-Free Remissions in Newly Diagnosed CP CML Patients Treated with the Combination of Nilotinib + Pegylated Interferon Alpha 2a Versus Nilotinib Alone in the National Phase III Petals Trial

Blood (2021) 138 (Supplement 1): 2553.

https://doi.org/10.1182/blood-2021-146412

Published: 2021

Journal Articles

Treatment Free Survival (TFS) in Patients (pts) with Chronic Myeloid Leukemia (CML) Carrying Atypical BCR-ABL1 Fusion Transcripts: The French CML Group (Fi-LMC) Experience

Hyacinthe Johnson-Ansah, Aude Charbonnier, Delphine Rea, Gabriel Etienne, Lydia Roy, Laurence Legros, Agnes Guerci Bresler, Anne Bouvier, Emilie Cayssials, Valerie Coiteux, Philippe Rousselot, Stephanie Dulucq, Sandrine Hayette, Francois-Xavier Mahon, Franck E. Nicolini

Blood (2021) 138 (Supplement 1): 3604.

https://doi.org/10.1182/blood-2021-147537

Published: 2021

Journal Articles

Cytokine-like protein 1–induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML

Blood (2021) 137 (24): 3390–3402.

https://doi.org/10.1182/blood.2020008729

Published: 2021

Includes: Supplemental data

Journal Articles

Therapy Related Myeloid Neoplasm Post PARP Inhibitors: Potential Clonal Selection.

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-139971

Published: 2020

Journal Articles

Long-Term Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line

Franck E Nicolini, MDPhD, Vincent Alcazer, MD, Pascale Cony-Makhoul, MD, Stephanie Dulucq, PharmD, PhD, Sandrine Hayette, PhD, Stephane Morisset, BioStat, Jean-Michel Cayuela, PharmD, PhD, Marie-Pierre Fort, PhD, Christophe Bouvier, CRA, Clemence Deteix-Santana, MD, Etienne Lengline, MD, Delphine Rea, MDPhD, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-139921

Published: 2020

Journal Articles

Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML

Jorge E. Cortes, MD, Jane Apperley, FRCP, FRCPath, MB, Andreas Hochhaus, MD, Michael J. Mauro, MD, Philippe Rousselot, MDPhD, Tomasz Sacha, MDPhD, Moshe Talpaz, MD, Charles Chuah, MD, Jeffrey H. Lipton, MD PhD, Michael W. Deininger, MD PhD, Charles A. Schiffer, MD, Lori J. Maness, MD, James K. McCloskey, MD, Valentín García Gutiérrez, MD PhD, Hugues de Lavallade, MD PhD, Gabriel Etienne, MD PhD, Vickie Lu, PhD, Shouryadeep Srivastava, MBBS, PhD, Gianantonio Rosti, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-135883

Published: 2020

Journal Articles

Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial

Blood (2020) 136 (Supplement 1): 47–50.

https://doi.org/10.1182/blood-2020-139677

Published: 2020

Journal Articles

Prospective Evaluation of ABL Kinase Domain Mutational Analysis By Next-Generation-Sequencing in Newly Diagnosed CP CML Patients Undergoing First-Line Treatment with Nilotinib Alone or Nilotinib + Pegylated Interferon-α2a in a Prospective Phase III Trial

Hugues de Lavallade, MD PhD, Sophie Jackson, BSc, Aytug Kizilors, PhD, Gabriel Etienne, MD PhD, Francoise Huguet, MD, Agnes Guerci-Bresler, MD PhD, Delphine Rea, MD, Claudine Chollet, MSc, Stephane Morisset, BioStat, Fanny Robbesyn, BSc, Francois-Xavier Mahon, MD PhD, Stephanie Dulucq, PharmD, PhD, Franck E Nicolini, MD PhD

Blood (2019) 134 (Supplement_1): 664.

https://doi.org/10.1182/blood-2019-125108

Published: 2019

Journal Articles

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Blood (2019) 134 (Supplement_1): 494.

https://doi.org/10.1182/blood-2019-123674

Published: 2019

Journal Articles

Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase" Reveals Induction of Early Molecular Responses in Patients with TKI-Resistant or Intolerant CML

Agnès Guerci, MD PhD, Emilie Cayssials, MD, Philippe Rousselot, MD PhD, Francoise Huguet, MD, Valerie Coiteux, MD, Marc G. Berger, MD PhD, Gabriel Etienne, MD PhD, Ali G Turhan, MD PhD

Blood (2019) 134 (Supplement_1): 5908.

https://doi.org/10.1182/blood-2019-122769

Published: 2019

NARROW

Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of Tyrosine Kinase Inhibitor Treatment Failure: A Report from the Residiag Study

Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study

T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Last Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase” in Patients with TKI-Resistant or Intolerant CML

Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group

Treatment Patterns, Tolerance, and Clinical Response of Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients (Including Those Harboring the T315I Mutation) Experiencing Multiple Tyrosine Kinase Inhibitor Failure: A Multi-Center Retrospective Chart Review Analysis

Therapy Related Myeloid Neoplasms Following PARP Inhibitors : Real-Life Experience

Prospective Follow-up of Patients with Myelofibrosis (MF) and Treated with Ruxolitinib in France: The Rumycup Study

Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line, in Real-Life Conditions: Influence of Switching to Another TKI Prior to Cessation.

The Outcome of Treatment-Free Remission after First-Line Nilotinib or Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients Is Different

Treatment-Free Remissions in Newly Diagnosed CP CML Patients Treated with the Combination of Nilotinib + Pegylated Interferon Alpha 2a Versus Nilotinib Alone in the National Phase III Petals Trial

Treatment Free Survival (TFS) in Patients (pts) with Chronic Myeloid Leukemia (CML) Carrying Atypical BCR-ABL1 Fusion Transcripts: The French CML Group (Fi-LMC) Experience

Cytokine-like protein 1–induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML

Therapy Related Myeloid Neoplasm Post PARP Inhibitors: Potential Clonal Selection.

Long-Term Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line

Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML

Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial

Prospective Evaluation of ABL Kinase Domain Mutational Analysis By Next-Generation-Sequencing in Newly Diagnosed CP CML Patients Undergoing First-Line Treatment with Nilotinib Alone or Nilotinib + Pegylated Interferon-α2a in a Prospective Phase III Trial

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase" Reveals Induction of Early Molecular Responses in Patients with TKI-Resistant or Intolerant CML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only